Similar results are shown in staining tumor cells with clinically approved anti-PD-L1 antibodies: Durvalumab, Avelumab, and Atezolizumab (Supplementary Fig. 1A1-6 for MDA-MB231 cells and B1-6 for MCF7 cells). This evidence concerns the gene CD274 and neoplasm.